Business context and reporting period
Vertex Pharmaceuticals Incorporated filed this Form 10-Q for the quarter ended September 30, 2014. The company focuses on cystic fibrosis (CF) medicines and research and development; it also continued winding down its hepatitis C virus (HCV) activities. The figures below are unaudited. Dollar amounts are in millions unless stated otherwise.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $179.0 | $221.7 | $435.9 | $860.8 |
| Operating loss | $(142.2) | $(123.6) | $(538.8) | $(599.7) |
| Net loss attributable to Vertex | $(170.1) | $(124.1) | $(561.9) | $(489.3) |
| Diluted net loss per share | $(0.72) | $(0.54) | $(2.40) | $(2.20) |
Q3 product revenue was $137.1 million: KALYDECO $126.8 million and INCIVEK $10.3 million. For the first nine months, product revenue was $362.9 million: KALYDECO $339.4 million and INCIVEK $23.5 million. Nine-month royalty revenue was $32.1 million and collaborative revenue was $40.8 million.
For the nine months, operating cash flow was $(391.3) million, compared with $(80.4) million in 2013. Investing activities provided $100.0 million and financing activities provided $441.1 million; cash and cash equivalents increased by $149.3 million to $718.6 million. At September 30, cash, cash equivalents and marketable securities totaled $1.478 billion, up $12.7 million from December 31, 2013.
Total liabilities were $1.250 billion, including a $294.7 million senior secured term loan, a $473.2 million construction financing lease obligation and $60.3 million of capital lease obligations. Shareholders’ equity was $1.156 billion. The term loan’s $300 million principal was borrowed in July 2014; principal repayment begins in 2015.
Material changes versus comparable periods
- Revenue declined 19% in Q3 and 49% for the first nine months, chiefly because INCIVEK sales and Janssen’s INCIVO royalty payments fell. KALYDECO revenue growth partly offset those declines.
- INCIVEK product revenue fell 88% in Q3 and 95% for the first nine months. KALYDECO product revenue rose 25% and 30%, respectively.
- Q3 collaborative revenue increased to $33.5 million, primarily reflecting a $30 million upfront payment from Janssen for an influenza-drug license.
- Q3 operating expenses fell 7%, while restructuring expense rose to $40.8 million, mainly for the Boston headquarters relocation and Cambridge facility closures.
- Nine-month 2014 net loss was higher than in 2013 despite lower total operating costs. The 2013 period included a $412.9 million VX-222 impairment charge and a related $127.6 million tax benefit; the resulting net increase in 2013 loss attributable to Vertex was $285.3 million. Alios results were presented as discontinued operations, affecting comparability.
Outlook, management commentary, risks and unusual items
- Management expected quarterly losses to continue and said available cash, cash equivalents and marketable securities, together with KALYDECO cash flows, should fund operations for at least the next 12 months. Future liquidity depends on product sales, reimbursement, research spending and regulatory outcomes.
- Vertex submitted an NDA to the FDA and an MAA to the EMA in November 2014 for lumacaftor plus ivacaftor in CF patients aged 12 and older with two F508del mutations. Management did not expect U.S. revenue before at least mid-2015; approval, launch timing and international reimbursement remained uncertain.
- Management expected Q4 KALYDECO revenue to decline from Q3, partly because a U.S. distribution-model change accelerated some orders into Q3. It did not expect significant future INCIVEK revenue.
- Vertex planned to begin Phase 3 trials of VX-661 with ivacaftor in the first half of 2015, subject to trial data and regulatory discussions. It also expected development outsourcing costs to rise as planned trials began.
- The $300 million term loan bears an initial 7.2% interest rate, has a July 2017 maturity, is secured by substantially all company and guarantor assets, and includes a minimum KALYDECO revenue covenant and other restrictions. No default was reported as of September 30, 2014. Management estimated Q4 interest expense of approximately $20 million, including headquarters lease-related interest.
- In April, Vertex received a one-time $36.7 million landlord payment, recorded as other income. In October, it notified Alios that the collaboration would terminate in December 2014; Alios was reported as discontinued operations.
- A shareholder class action alleges securities-disclosure misrepresentations concerning May 2012. Vertex said it considered the claims without merit and intended to defend the case; it had recorded no reserve. No material contingent liabilities were accrued at September 30.
- Management identified approval and reimbursement of lumacaftor plus ivacaftor as a key business risk. The filing also describes clinical-development, regulatory, pricing, liquidity and debt-covenant risks.
Important facts for investors to verify
- Progress, review timelines, labeling and potential reimbursement for lumacaftor plus ivacaftor, and whether launch timing supports management’s revenue expectations.
- KALYDECO sales trends after the Q3 ordering acceleration, label expansions, and international reimbursement developments.
- Operating cash burn, cash and marketable-securities levels, and funding needs as debt principal repayments and planned clinical-trial spending increase.
- Compliance with the term loan’s KALYDECO revenue covenant, repayment schedule and restrictions, along with future interest and lease obligations.
- Developments in the shareholder litigation, restructuring costs, and the termination and remaining obligations associated with Alios.